Our Leadership Team
Robert J. Beckman was a founder and for 14 years CEO of Intergen Company, a private company that supplied a wide array of biological products and innovative technologies to the life sciences industry. Intergen was profitable for nearly every year of its existence from its inception as a management acquisition until its sale. Mr. Beckman previously served as Vice President, Marketing Services, at Revlon Health Care Group (which included USV Pharmaceutical Corp. and Armour Pharmaceutical Co.) until he was appointed Vice President and General Manager of the Biochemical and Diagnostic Division of Revlon Healthcare Group. Upon the sale of Revlon's pharmaceutical businesses to Rorer, Mr. Beckman continued in this position until he co-founded Intergen. Mr. Beckman grew Intergen through internal product development and also through the acquisition of five companies; created business units in Canada, Europe, and Japan; established significant manufacturing capacities; and developed an extensive portfolio of medical technology that Intergen sold and licensed.
Mr. Beckman served on the Executive Committee and was Chairman of the Corporate Governance Committee of the Board of E-Z-EM, Inc. (NasdaqGS: EZEM), a provider of medical imaging products, prior to its acquisition in April 2008 by Bracco Diagnostics Inc., the U.S.-based subsidiary of Bracco Imaging SpA and part of the Bracco Group. He currently serves on the Board of Directors at Innovea Medical Ltd, a diagnostic imaging company based in Israel, and is on the Board of Lesanne Life Sciences, LLC, a company co-founded by The Channel Group. In addition, he previously served as a member of the Board of Directors and management of Phage Pharmaceuticals, Inc., a specialty biopharmaceutical manufacturer and developer of therapeutic proteins, and served on the Board of Directors of LCT BioPharma Inc., the U.S. subsidiary of Living Cell Technologies Limited (ASX:LCT). Mr. Beckman holds a B.S. Pharm degree from Columbia University and is a co-founder and Managing Partner of The Channel Group.
Philip N. Sussman served as a member of senior management (Head of Business Development, CFO, and CEO) of several public and private biotechnology companies, including Perlegen Sciences, Inc., Memory Pharmaceuticals Corp., and Cadus Pharmaceutical Corp. In these positions he established collaborations with major pharmaceutical companies, including AstraZeneca AB, Bristol-Myers Squibb Co., Eli Lilly & Co., GlaxoSmithKline plc, Pfizer Inc., Solvay Pharmaceuticals B.V., and Unilever plc that provided in aggregate more than $100 million in research funding and equity investments. His deal sheet lists 27 significant life sciences transactions, including an IPO on NASDAQ. He also initiated and was responsible for in-licensing of late-stage clinical and pre-clinical drug candidates. Prior to those positions, he was Director of Strategy & Business Development at Ciba-Geigy Corp.'s (now Novartis) Pharmaceuticals Division.
Mr. Sussman is on the Board of Thar Pharmaceuticals, Inc. and a founder and member of the Board of Lesanne Life Sciences, LLC, a company co-founded by The Channel Group. He was a member of the Board of LCT BioPharma Inc., the U.S. subsidiary of Living Cell Technologies Limited (LCT: ASX). In addition, he previously served as a member of the Board of Directors and management of Phage Pharmaceuticals, Inc., a specialty biopharmaceutical manufacturer and developer of therapeutic proteins. Mr. Sussman has a B.S. in Physics from the State University of New York at Stony Brook, a Master of Science in Biotechnology from Manhattan College, and an S.M. in Management with a concentration in Finance from the Sloan School of Management, MIT. He is a Managing Partner of The Channel Group.
Vijay Aggarwal, Ph.D., a Managing Partner of The Channel Group, has more than 30 years of senior executive experience in both pharmaceutical services and clinical diagnostics. Previously, Dr. Aggarwal was CEO of VaxiGenix, Inc., an early-stage therapeutic vaccine company developing companion diagnostics and treatments for colorectal cancer. Dr. Aggarwal was President and CEO of Aureon Laboratories, Inc., a venture capital-backed predictive pathology company offering advanced tissue analysis services to practicing physicians and the pharmaceutical industry. Previously, he was President of AAI Development Services, Inc., a contract research and development services company serving the pharmaceutical and biotech industries. Prior to that appointment, he was President of Quest Diagnostic Ventures, where he had responsibility for new technology, new business models, clinical trials testing, and direct-to-consumer strategies.
Earlier in his career, Dr. Aggarwal held many positions within SmithKline Beecham Clinical Laboratories ("SBCL"), the clinical laboratory operations of SmithKline Beecham plc, including direct responsibility for all of SBCL's U.S.-based laboratories as Executive Vice President of Laboratories and responsibility for all reimbursement contracting as Vice President of Managed Care. Dr. Aggarwal currently serves on the boards of several private diagnostic companies, including: AccuGenomics, Inc.; Genisphere LLC; Hycor Biomedical, Inc.; Mitomics Inc.; Targeted Diagnostics and Therapeutics, Inc.; and Viracor-IBT Laboratories. He earned a Ph.D. in Pharmacology/Toxicology from the Medical College of Virginia.
Walter Flamenbaum, M.D. is a Managing Partner of The Channel Group. He was a Founding Partner of Paul Capital Healthcare Funds, which have invested over $1 billion in forty investments, and is currently a Partner Emeritus at Paul Capital. He has led the development and refinement of its investment strategy, processes, and techniques — as well as actively participating in the majority of the Fund's investments, including roles in sourcing, negotiating and other activities. He was primarily responsible for the development of the diverse team of healthcare and financial investment professionals, allowing for the Fund's development and successes to date. Dr. Flamenbaum's healthcare experience includes the development and evaluation of pharmaceutical and biotechnology-based drugs, medical devices, and diagnostics. During the ten years prior to joining Paul Capital Partners in 1999, he had extensive experience in the licensing of healthcare product related intellectual properties and the assessment of healthcare investing opportunities. He also founded a contract research organization, started a biomedical company, and had senior management responsibilities in a biotechnology company.
Dr. Flamenbaum is on the Board of Directors of OSE Pharma SA, Allergen Research Corporation, Norphan Pharmaceuticals, Inc., UMAN Pharma Inc., and Heart Metabolics Ltd. He is board certified in internal medicine, nephrology, and clinical pharmacology and was a professor of medicine at the Mt. Sinai School of Medicine and Tufts University School of Medicine. Dr. Flamenbaum served in the U.S. Army at the Walter Reed Army Institute of Research and the Walter Reed Army Medical Center. He earned a B.A. from Washington & Jefferson College and an M.D. from Columbia University's College of Physicians & Surgeons.
Stephen H. Blose, V.M.D, Ph.D., Managing Partner of The Channel Group, has more than 27 years of executive management experience in building successful life sciences, diagnostics, and medical device businesses. He is the founder of the Mill Valley Summit Group, LLC. Since inception, the group has helped over 20 early-stage companies raise more than $102-million through venture financings and licensing and asset transactions. It also provides investment advice to U.S. and German venture capital firms. Previously, Dr. Blose served as General Manager of Bio-Rad Laboratories Inc.'s Imaging Products Division, a position he assumed upon Bio-Rad's acquisition of Protein Databases, Inc., where he served as CEO. During his tenure at Protein Databases, the company developed significant relationships with Millipore Corporation, Pharmacia LKB Biotechnology (now GE Healthcare), and Toyobo Co., Ltd. Prior to that he was a Senior Scientist in the laboratory of Nobel Laureate James D. Watson at Cold Spring Harbor Laboratory, conducting research on cancer proteomics. He is regarded as one of the founders of the proteomics industry.
Dr. Blose is the former Chairman of the Board of Directors and Audit Committee member of BioMicro Systems, Inc. (sold to Hoffman La-Roche Diagnostics), Board Director and Board Secretary of Sentrx Animal Care, Inc., Board Secretary and Chief Business Officer of Lumiphore, Inc., and a Founding Director of the New York Biotechnology Association. He earned a Ph.D. in experimental pathology from the University of Pennsylvania and a V.M.D. from the University of Pennsylvania. Dr. Blose is based in the San Francisco Bay area.
Anthony A. Lombardo, Partner of The Channel Group, is the immediate past Chief Operating Officer of Bracco Diagnostics, Inc., the major operating unit of The Bracco Group, a private healthcare company based in Milan that has worldwide annual sales of over one billion dollars. He has broad experience across medical device and imaging technologies. Previously, Mr. Lombardo was President & CEO of E-Z-EM Inc. a company focusing on oral imaging contrast agents. He joined E-Z-EM to effect a turnaround of this publicly-traded company. He created shareholder value through a tax-free spinout of AngioDynamics, Inc., developing new products, and the subsequent sale of E-Z-EM to Bracco Diagnostics. The actions he took to transform the company led in eight years to a combined exit value of approximately $450 million, up from a market value of approximately $10 million at the time that he joined the company.
Prior to that, Mr. Lombardo served as President of Ali Imaging Systems, Inc., which he built into a first-tier Ultrasound PACS player. Subsequently, it was sold to McKesson Corporation for approximately $340 million. Prior to that he served as General Manager of Integrated Imaging Solutions at General Electric Co.'s Medical Systems Division, a company he first worked at immediately after finishing his graduate studiesHe also served as President of the Medical Systems Division of Loral/Lockheed Martin Corp. and Vice President and General Manager of the Medical Systems Division of Sony Corporation. Mr. Lombardo has recently been honored by the American College of Radiology and the Society of Abdominal Radiology for his years of service to the clinical community. He serves as Chairman of the Advisory Board of Morristown Medical Center a part of Atlantic Health System Hospitals. He received a B.S. in Biology from St. Francis College and an M.S. in Physiology from Duquesne University. He was a Ph.D. candidate at Cornell Medical School in cardiovascular physiology.
David E. Jackson, Partner of BioMed Transition Partners, was most recently VP of Operations Planning at Phage Pharmaceuticals, Inc., where he was responsible for oversight of the company's cGMP-certified therapeutic protein manufacturing facility in San Diego. Prior to that position, Mr. Jackson was the VP of Process Development and Manufacturing at VaxInnate Corp., where he was responsible for creating Development, QA/QC, and Regulatory teams, and as well as for building the company's infrastructure and overseeing capital projects. He previously was VP of U.S. Operations and later VP of Global Biologics Manufacturing at Lonza Biologics Inc., a wholly-owned subsidiary of Lonza Group Ltd. (Switzerland), where he was responsible for greenfield site construction and other capital projects, as well as technology transfer and GMP contract manufacturing. He also served as VP of Manufacturing at BioReliance Corp. and VP of Manufacturing and Pharmaceutical Support at EntreMed, Inc.
The therapeutic proteins that Mr. Jackson has taken from the bench into pre-clinical, clinical, and marketed supply include: Hu Factor VIII, Hu Factor XI, Albumin, IgG, Alpha-1 Antitrypsin, Anti Thrombin III, Activated Protein C, Thrombin, Plasminogen/ Plasmin, Growth Hormone, and FSH. The vaccine projects that he has taken from the bench into pre-clinical, clinical, and manufacturing include: influenza subunit vaccines for Solomon Islands, New Caledonia, a universal influenza vaccine against M2, Vietnamese (H5N1), other HA and B strains of influenza, West Nile, Liposomal FGF, Small Pox, Japanese Encephalitis, and HIV. Mr. Jackson served honorably in the United States Marine Corps and received a B.A. in Chemistry from Olivet Nazarene University.
Shmuel Einav, Ph.D. is an Advisory Partner at The Channel Group. Dr. Einav has made seminal contributions to the field of biomedical engineering through his studies on the cardiovascular circulatory system. He is currently Professor of Biomedical Engineering and Director, Medical Technologies Division, Center of Excellence for Wireless and Information Technologies at Stony Brook University. As Director of Ramot-University Authority for Applied Research and Industrial Development Ltd., the technology transfer organization of Tel Aviv University, he initiated more than 15 start-up companies and managed $30 million in assets and 90 employees.
Dr. Einav also was a founder or advisor to several medical device companies, including: NiCast, Ltd., a developer and marketer of bio-impedance based cardiac monitors; Florence Medical Ltd., a stent and cardiovascular diagnostic technology company; IntelliDX Inc. (formerly Glucon, Inc.), a developer and marketer of a blood glucose testing system for monitoring hospital patients who have abnormally elevated sugar levels; and, Ventor Technologies Ltd., a developer of trans-catheter heart valve technologies that was acquired by Medtronic, Inc. for $325 million in 2009. He was also a member of the advisory board of several venture capital funds, including Veritas Venture Partners, InnoMed Fund of Jerusalem Global Ventures, and Ramot Medical Fund. Dr. Einav is Emeritus Professor and Incumbent of the Herman Berman Chair for Vascular Bioengineering at Tel Aviv University. He earned a B.Sc. and a M.Sc. in Mechanical and Nuclear Engineering from the Technion (Israel), and a Ph.D. in Biomedical Engineering from Stony Brook University.
Allan R. Goldberg, Ph.D. has been instrumental in the formation and development of a number of start-up companies. He held various senior management positions including chairman and chief executive officer and chief scientific officer at Innovir Laboratories, Inc., a NASDAQ-listed biotechnology company he co-founded. Dr. Goldberg was a co-founder and director of ZyStor Therapeutics, Inc., a Milwaukee-based biotechnology company that developed a protein manufacturing and delivery platform technology for the treatment of various lysosomal storage diseases, including an enzyme-based protein therapeutic for Pompe disease that is currently in a Phase I/II clinical trial. BioMarin Pharmaceuticals Inc. (NasdaqNM: BMRND) acquired ZyStor in August, 2010. Dr. Goldberg currently serves on the Board of Directors of Astex Pharmaceuticals, Inc. (NasdaqNM: STX). In addition, he has been on the Board of Directors of LCT BioPharma Inc., the U.S. subsidiary of Living Cell Technologies Limited (ASX:LCT), and on the Board of Lesanne Life Sciences, LLC, a company co-founded by The Channel Group. In addition, he previously served as a member of the Board of Directors and management of Phage Pharmaceuticals, Inc., a specialty biopharmaceutical manufacturer and developer of therapeutic proteins. He is President and CEO and a founder of Avacyn Pharmaceuticals, Inc., a biotechnology company developing a new generation of anti-bacterial drugs. He is President and CEO and a founder of Avacyn Pharmaceuticals, Inc., a biotechnology company developing a new generation of anti-bacterial drugs.
Prior to involvement with Innovir, Dr. Goldberg was a professor of virology and a Richard King Mellon Foundation Fellow at The Rockefeller University from 1971 to 1989. Dr. Goldberg has served as a consultant to several large pharmaceutical companies as well as numerous private and public academic institutions. He earned a B.A. from Cornell University and a Ph.D. from Princeton University, and was a postdoctoral fellow at Albert Einstein College of Medicine. He is a co-founder and Partner Emeritus of The Channel Group.